cephalon, the maker of the 'vigils', gives money to Stanford. I find this a bit suspicious as decreasing rx'es written for the traditional 'stimmies' will increase sales of the 'vigils'. I encountered a lot of hostility toward my Adderall regime at Stanford during my visits there in an evaluation in '10, also from the office of the director, dr mignot, later after I emailed a request for Stanford to have different md attending me to dr mignot.
in being fair I must make it clear that dr mignot's email address is not where my reply/replies to the inquiry came from. nevertheless the email replied to was sent to dr mignot. repeated attempts sent to dr mignot by me asking his confirmation or his disavowal, whichever is applicable, of these replies have been/are met w/silence.
a recent ('12) paper by dr mignot, the director there, A PRACTICAL GUIDE TO THE TREATMENT OF NARCOLEPSY AND OTHER HYPERSOMNIA SYNDROMES takes a dim view of the amphetamines as a tx option for eds. a previous paper by dr mignot PHARMACOLOGICAL ASPECTS OF HUMAN AND CANINE NARCOLEPSY does not. in fact it acknowledges high doses of same as indicated/neccesary in some patients on pg 37. very high doses.
could this older (96) paper reflect a medical position prior to cephalon $$$ incentive, inappropriately influenced by same to some degree at least?
DISCLAIMER: I an aware dr mignot has done pwn a lot of good, and he is a great md. only his position on amphetamines apprears to me questionable.